<DOC>
	<DOCNO>NCT00220532</DOCNO>
	<brief_summary>This randomise double-blind placebo-controlled trial see whether give low dose vitamin folic acid riboflavin beneficial woman low grade abnormality cervical cell .</brief_summary>
	<brief_title>Folate Protection Against Cervical Cancer</brief_title>
	<detailed_description>The overall aim study evaluate interaction intake folic acid riboflavin common polymorphism relevant folate metabolism , determine risk cervical cancer woman carry high risk human papillomavirus . We test follow hypothesis : Supplements riboflavin folic acid increase rate regression low grade cervical intra epithelial neoplasia ( CIN1 ) . Effects supplemental folic acid riboflavin CIN1 regression modulate common polymorphism MTHFRC677T gene . We recruit woman biopsy-proven CIN1 carry high risk HPV infection , randomise 12month intervention 1.2mg folic acid 5mg riboflavin placebo . The primary outcome regression biopsy-proven CIN1 , secondary outcome include measure DNA stability .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Riboflavin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>biopsydiagnosed CIN1 infection oncogenic HPV Any stage cervical abnormality pregnant planning pregnancy diabetic taking B vitamin supplement take antiepileptic treatment take methotrexate bleeding intercourse abnormal GI function infection chlamydia , HIV agent</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Randomised placebo control intervention trial</keyword>
	<keyword>Folic acid</keyword>
	<keyword>Riboflavin</keyword>
	<keyword>cervical cancer</keyword>
</DOC>